Clinica Chimica Acta:三种手持式即时护理肌酐分析仪在造影剂增强成像前进行肾功能测量的分析和临床表现

2019-11-23 MedSci MedSci原创

由于碘基造影剂可导致肾功能受损患者肾功能恶化,因此,指南建议在给药前测量肌酐并计算估计的肾小球滤过(eGFR)。床旁检测(POC)设备似乎是一个有吸引力的替代中心实验室测试的策略,但不确定的分析和临床可比性仍然存在。

由于碘基造影剂可导致肾功能受损患者肾功能恶化,因此,指南建议在给药前测量肌酐并计算估计的肾小球滤过(eGFR)。床旁检测(POC)设备似乎是一个有吸引力的替代中心实验室测试的策略,但不确定的分析和临床可比性仍然存在。

本研究将三种POC设备(i-STAT (Abbott)StatSensor (Nova)epoc (Siemens))与中心实验室方法(酶法肌酐、Siemens Vista 1500平台)进行了比较。研究人员收集了120例患者,对他们同时进行了StatSensor上的手指穿刺毛细血管血分析和StatSensori-STATepoc上的肝素全血分析。

所有POC装置产生的结果均显示在参考标准的肌酐值附近有相当大的可变性,其中StatSensor95%区间最大(-1,12-1,11 mg / dL),而epoc95%区间(-0,49-0,49 mg / dL)最小。 与参考标准相比,I-STAT与参考标准的临床一致性最高(Kappa0.94),并且肌酐和eGFR的平均分析误差最小(6%),可满足8.87%的预定标准和 分别为10%。 Epoc仅符合eGFR标准。 StatSensor不符合任何标准。

研究表明,从分析和临床的角度来看,I-STATepoc是本研究中包含的性能最好的POC设备,但它们的用户友好度较低。StatSensor不符合任何一个错误标准,无论是肌酐还是eGFR的测量,并且给出了更多的临床主要分类错误。然而,与其他POC设备相比,它的用户友好度好不错。

原始出处:

Catharina van der HeijdenLaurence RoosensAnalytical and clinical performance of three hand-held point-of-care creatinine analyzers for renal function measurements prior to contrast-enhanced imaging

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1850728, encodeId=a00c1850e28fa, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sat Sep 26 10:02:00 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849788, encodeId=98c61849e88bd, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Feb 11 07:02:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293433, encodeId=c3e0129343374, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Nov 25 12:02:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494132, encodeId=744d14941329f, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Mon Nov 25 12:02:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2020-09-26 yese
  2. [GetPortalCommentsPageByObjectIdResponse(id=1850728, encodeId=a00c1850e28fa, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sat Sep 26 10:02:00 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849788, encodeId=98c61849e88bd, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Feb 11 07:02:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293433, encodeId=c3e0129343374, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Nov 25 12:02:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494132, encodeId=744d14941329f, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Mon Nov 25 12:02:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2020-02-11 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=1850728, encodeId=a00c1850e28fa, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sat Sep 26 10:02:00 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849788, encodeId=98c61849e88bd, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Feb 11 07:02:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293433, encodeId=c3e0129343374, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Nov 25 12:02:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494132, encodeId=744d14941329f, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Mon Nov 25 12:02:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2019-11-25 俅侠
  4. [GetPortalCommentsPageByObjectIdResponse(id=1850728, encodeId=a00c1850e28fa, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sat Sep 26 10:02:00 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849788, encodeId=98c61849e88bd, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Feb 11 07:02:00 CST 2020, time=2020-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293433, encodeId=c3e0129343374, content=<a href='/topic/show?id=1d44810e5f7' target=_blank style='color:#2F92EE;'>#肌酐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81075, encryptionId=1d44810e5f7, topicName=肌酐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Nov 25 12:02:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494132, encodeId=744d14941329f, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Mon Nov 25 12:02:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2019-11-25 sodoo